NuCana (NCNA) Stock Price, News & Analysis

Company Overview

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Key Stats

• Today's Range: $1.25 to $1.29
• 50-Day Range: $1.29 to $6.37
• 52-Week Range: $1.25 to $19.41
• Volume: 99,644 shs
• Average Volume: 446,430 shs
• Market Capitalization: $3.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Moderate Buy

NuCana Stock Analysis - MarketRank™

NuCana scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NuCana has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

NuCana has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NuCana are expected to grow in the coming year, from ($13.20) to ($10.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NuCana is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NuCana is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NuCana has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.01% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently decreased by 35.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NuCana does not currently pay a dividend.

Dividend Growth

NuCana does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.01% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently decreased by 35.40%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for NCNA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NuCana insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NCNA Stock Analysis - Frequently Asked Questions

How have NCNA shares performed this year?

NuCana's stock was trading at $7.3950 at the beginning of the year. Since then, NCNA stock has decreased by 82.8% and is now trading at $1.27.
View the best growth stocks for 2024 here.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) released its earnings results on Wednesday, November, 17th. The company reported ($375.00) EPS for the quarter, topping analysts' consensus estimates of ($462.58) by $87.58.

When did NuCana's stock split?

NuCana's stock reverse split before market open on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did NuCana IPO?

NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

Who are NuCana's major shareholders?

NuCana's top institutional investors include Baillie Gifford & Co. (1.39%).

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NuCana own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Plug Power (PLUG), SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 11/17/2021
• Today: 11/21/2024
• Next Earnings (Estimated): 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NCNA
• CUSIP: N/A
• CIK: 1709626
• Web: www.nucana.com
• Phone: 441313571111
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +1,868.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($12.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,370,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -222.73%
• Return on Assets: -105.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.08
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.85 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 2,640,000
• Free Float: 1,818,000
• Market Cap: $3.35 million
• Optionable: Not Optionable
• Beta: 1.03